Literature DB >> 15995627

PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system.

Yan-Bing Ding1, Rui-Hua Shi, Jian-Dong Tong, Xiao-Yu Li, Guo-Xin Zhang, Wei-Ming Xiao, Jian-Guo Yang, Yun Bao, Jian Wu, Zhi-Gang Yan, Xue-Hao Wang.   

Abstract

AIM: 1) To evaluate the effect of prostaglandin E2 (PGE2) on the regulation of vascular endothelial growth factor (VEGF) expression in gastric MKN28 cells, and 2) to investigate the role of the epidermal growth factor receptor (EGFR) signal transduction pathway in any effect exerted by PGE2 on VEGF expression.
METHODS: MKN28 cells were incubated with the vehicle (control) or with PGE2 in the presence or absence of AG1478, a selective inhibitor of EGFR tyrosine kinase, or PD098059, a selective inhibitor of the kinase responsible for ERK2 phosphorylation (mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK)). Real-time quantitative polymerase chain reaction and Western blot analysis were used to evaluate VEGF mRNA and protein expression. The activity of EGFR and ERK2 was measured by Western blot analysis.
RESULTS: PGE2 significantly up-regulated VEGF mRNA and protein expression and increased the activation of EGFR and ERK2. Incubation of MKN28 cells with AG1478 significantly reduced PGE2-induced EGFR activity, ERK2 activity, and VEGF mRNA and protein expression. Meanwhile, incubation of MKN28 with PD098059 reduced PGE2-induced ERK2 activity and VEGF mRNA and protein expression, but had no effect on EGFR activity.
CONCLUSION: Our data suggested that PGE2 up-regulates VEGF expression in gastric cancer cells via transactivation of EGFR-MAPK signaling pathways, which may be mechanisms underlying the contribution of COX-2 to tumor angiogenesis in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15995627

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  7 in total

1.  Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.

Authors:  Neil E Bhola; Maria L Freilino; Sonali C Joyce; Malabika Sen; Sufi M Thomas; Anirban Sahu; Andre Cassell; Ching-Shih Chen; Jennifer R Grandis
Journal:  Mol Cancer Ther       Date:  2012-04-05       Impact factor: 6.261

Review 2.  Eicosanoids and cancer.

Authors:  Dingzhi Wang; Raymond N Dubois
Journal:  Nat Rev Cancer       Date:  2010-02-19       Impact factor: 60.716

3.  Induction of myeloid-derived suppressor cells by tumor exosomes.

Authors:  Xiaoyu Xiang; Anton Poliakov; Cunren Liu; Yuelong Liu; Zhong-bin Deng; Jianhua Wang; Ziqiang Cheng; Spandan V Shah; Gui-Jun Wang; Liming Zhang; William E Grizzle; Jim Mobley; Huang-Ge Zhang
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

4.  MYEOV (myeloma overexpressed gene) drives colon cancer cell migration and is regulated by PGE2.

Authors:  Garrett Lawlor; Peter P Doran; Padraic MacMathuna; David W Murray
Journal:  J Exp Clin Cancer Res       Date:  2010-06-22

Review 5.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

6.  Gastric juice prostaglandins and peptide growth factors as potential markers of chronic atrophic gastritis, intestinal metaplasia and gastric cancer: their potential clinical implications based on this pilot study.

Authors:  Ajoy Dias; Cesar Garcia; Marek Majewski; Grzegorz Wallner; Richard W McCallum; Cezary Poplawski; Jerzy Sarosiek
Journal:  Dig Dis Sci       Date:  2011-06-22       Impact factor: 3.199

7.  Prostaglandin E2 breaks down pericyte-endothelial cell interaction via EP1 and EP4-dependent downregulation of pericyte N-cadherin, connexin-43, and R-Ras.

Authors:  Carole Y Perrot; Jose L Herrera; Ashley E Fournier-Goss; Masanobu Komatsu
Journal:  Sci Rep       Date:  2020-07-07       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.